Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 301–400 of 1,018
Reboussin, D. M., Allen, N. B., Griswold, M. E., Guallar, E., Hong, Y., Lackland, D. T., Miller, E. (. R., Polonsky, T., Thompson-Paul, A. M., & Vupputuri, S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.004 · Cited by 221
Gerdts, E., Wachtell, K., Omvik, P., Otterstad, J. E., Oikarinen, L., Boman, K., Dahlöf, B., & Devereux, R. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000254322.96189.85 · Cited by 221
Self-citationRe-examining the efficacy of -blockers for the treatment of hypertension: a meta-analysis
Khan, N. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060110 · Cited by 221
Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications
Kalil, G. Z., & Haynes, W. G. (2012) · Hypertension Research · doi:10.1038/hr.2011.173 · Cited by 221
Mackenzie, I. S., McEniery, C. M., Dhakam, Z., Brown, M. J., Cockcroft, J. R., & Wilkinson, I. B. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133801 · Cited by 221
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 220
Large and Small Artery Cross-Talk and Recent Morbidity-Mortality Trials in Hypertension
Laurent, S., Briet, M., & Boutouyrie, P. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133116 · Cited by 217
Management of Glomerular Proteinuria: A Commentary
Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100145.27188.33 · Cited by 217
White, W. B., Weber, M. A., Sica, D., Bakris, G. L., Perez, A., Cao, C., & Kupfer, S. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.163402 · Cited by 216
Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
Guidelines, S. (2006) · Hypertension Research · Cited by 216
Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
Japanese Society of Hypertension (2006) · Hypertension Research · doi:10.1291/hypres.29.s1 · Cited by 216
Yusuf, S., Ostergren, J. B., Gerstein, H. C., Pfeffer, M. A., Swedberg, K., Granger, C. B., Olofsson, B., Probstfield, J., & McMurray, J. V. (2005) · Circulation · doi:10.1161/circulationaha.104.528166 · Cited by 215
The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans
Underwood, P. C., & Adler, G. K. (2013) · Current Hypertension Reports · doi:10.1007/s11906-012-0323-2 · Cited by 215
Gillespie, E. L., White, C. M., Kardas, M., Lindberg, M., & Coleman, C. I. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2261 · Cited by 215
DIAMOND, J. A., & PHILLIPS, R. A. (2005) · Hypertension Research · doi:10.1291/hypres.28.191 · Cited by 213
Combination therapy in hypertension
Gradman, A. H., Basile, J. N., Carter, B. L., & Bakris, G. L. (2010) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2010.03.001 · Cited by 212
2024 Clinical practice guidelines for Hypertension in adults
Kobalava, Z. D., Konradi, A. O., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Baranova, E. I., Barbarash, O. L., Bobkova, N. V., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6117 · Cited by 211
Angiotensin receptor blockers and myocardial infarction
Verma, S., & Strauss, M. (2004) · BMJ · doi:10.1136/bmj.329.7477.1248 · Cited by 210
Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients
Krum, H., Nolly, H., Workman, D., He, W., Roniker, B., Krause, S., & Fakouhi, K. (2002) · Hypertension · doi:10.1161/01.hyp.0000025146.19104.fe · Cited by 210
Rate and determinants of 10-year persistence with antihypertensive drugs
Van Wijk, B. L., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000187261.40190.2e · Cited by 210
Voulgari, Tentolouris, N., & Papadogiannis, D. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11681 · Cited by 210
Surrogate Markers for Cardiovascular Disease: Structural Markers
Mancini, G. B. J., Dahlöf, B., & Díez, J. (2004) · Circulation · doi:10.1161/01.cir.0000133443.77237.2f · Cited by 210
Self-citationElliott, W. J. (2007) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2007.01.002 · Cited by 208
Johnston, S. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp020891 · Cited by 207
O’Keefe, J. H., Abuissa, H., Sastre, A., Steinhaus, D. M., & Harris, W. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.025 · Cited by 207
The cardiovascular continuum and renin–angiotensin–aldosterone system blockade
Dzau, V. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000165623.72310.dd · Cited by 207
Sim, J. J., Bhandari, S. K., Shi, J., Liu, I. L. A., Calhoun, D. A., McGlynn, E. A., Kalantar-Zadeh, K., & Jacobsen, S. J. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.06.017 · Cited by 206
Thomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001276 · Cited by 206
Takahashi, A., Takase, H., Toriyama, T., Sugiura, T., Kurita, Y., Ueda, R., & Dohi, Y. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl293 · Cited by 206
Thomopoulos, C., Parati, G., & Zanchetti, A. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000614 · Cited by 206
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 206
Drug-Induced Hyperglycaemia and Diabetes
Fathallah, N., Slim, R., Larif, S., Hmouda, H., & Ben Salem, C. (2015) · Drug Safety · doi:10.1007/s40264-015-0339-z · Cited by 205
Boutouyrie, P., Achouba, A., Trunet, P., & Laurent, S. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.148999 · Cited by 204
Rossi, A., Dikareva, A., Bacon, S. L., & Daskalopoulou, S. S. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283544669 · Cited by 203
Systematic Review: Antihypertensive Drug Therapy in Black Patients
Brewster, L. M., van Montfrans, G. A., & Kleijnen, J. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-8-200410190-00009 · Cited by 203
Chiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., et al. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.11.005 · Cited by 199
Nagata, D., Takeda, R., Sata, M., Satonaka, H., Suzuki, E., Nagano, T., & Hirata, Y. (2004) · Circulation · doi:10.1161/01.cir.0000136025.96811.76 · Cited by 198
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70147-7 · Cited by 197
A comparison of atenolol and nebivolol in isolated systolic hypertension
Dhakam, Z., Yasmin, McEniery, C. M., Burton, T., Brown, M. J., & Wilkinson, I. B. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f283c9 · Cited by 197
Heart failure with preserved ejection fraction: a clinical dilemma
Komajda, M., & Lam, C. S. P. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu067 · Cited by 197
Evaluation and Management of Diastolic Heart Failure
Angeja, B. G., & Grossman, W. (2003) · Circulation · doi:10.1161/01.cir.0000053948.10914.49 · Cited by 197
10-Year Risk Equations for Incident Heart Failure in the General Population
Khan, S. S., Ning, H., Shah, S. J., Yancy, C. W., Carnethon, M., Berry, J. D., Mentz, R. J., O’Brien, E., Correa, A., Suthahar, N., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.057 · Cited by 196
Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis
Candido, R., Allen, T. J., Lassila, M., Cao, Z., Thallas, V., Cooper, M. E., & Jandeleit-Dahm, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000124061.78478.94 · Cited by 195
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 194
Mohammed, N. A., Mahfouz, A., Achkar, K., Rafie, I., & Hajar, R. (2013) · Heart Views · doi:10.4103/1995-705x.125926 · Cited by 194
Inflammation and Atherosclerosis
Kaperonis, E. A., Liapis, C. D., Kakisis, J. D., Dimitroulis, D., & Papavassiliou, V. G. (2005) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2005.11.001 · Cited by 194
Dietz, R., & Rauch, B. (2003) · Zeitschrift für Kardiologie · doi:10.1007/s00392-003-0960-1 · Cited by 194
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
Vitale, C., Mercuro, G., Castiglioni, C., Cornoldi, A., Tulli, A., Fini, M., Volterrani, M., & Rosano, G. M. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-6 · Cited by 193
de Luca, N., Asmar, R. G., London, G. M., O'Rourke, M. F., & Safar, M. E. (2004) · Journal of Hypertension · doi:10.1097/01.hjh.0000125448.28861.fc · Cited by 192
Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction
Anderson, T. J. (2003) · Heart Failure Reviews · doi:10.1023/a:1022199021949 · Cited by 191
National Stroke Association guidelines for the management of transient ischemic attacks
Johnston, S. C., Nguyen‐Huynh, M. N., Schwarz, M. E., Fuller, K., Williams, C. E., Josephson, S. A., Hankey, G. J., Hart, R. G., Levine, S. R., Biller, J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20942 · Cited by 191
Chen, R., Suchard, M. A., Krumholz, H. M., Schuemie, M. J., Shea, S., Duke, J., Pratt, N., Reich, C. G., Madigan, D., You, S. C., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16667 · Cited by 190
Assessment and Management of Hypertension in Transplant Patients
Weir, M. R., Burgess, E. D., Cooper, J. E., Fenves, A. Z., Goldsmith, D., McKay, D., Mehrotra, A., Mitsnefes, M. M., Sica, D. A., & Taler, S. J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080834 · Cited by 190
Gray, B. H., Olin, J. W., Childs, M. B., Sullivan, T. M., & Bacharach, J. M. (2002) · Vascular Medicine · doi:10.1191/1358863x02vm456oa · Cited by 189
Mathiassen, O. N., Buus, N. H., Sihm, I., Thybo, N. K., Mørn, B., Schroeder, A. P., Thygesen, K., Aalkjaer, C., Lederballe, O., Mulvany, M. J., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e32805bf8ed · Cited by 188
Angiotensin-Converting Enzyme Inhibitors and Change in Aortic Valve Calcium
O’Brien, K. D., Probstfield, J. L., Caulfield, M. T., Nasir, K., Takasu, J., Shavelle, D. M., Wu, A. H., Zhao, X.-Q., & Budoff, M. J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.858 · Cited by 187
Cardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
Sciarretta, S., Palano, F., Tocci, G., Baldini, R., & Volpe, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.427 · Cited by 185
Mechanisms of target organ damage caused by hypertension: Therapeutic potential
Cohuet, G., & Struijker-Boudier, H. A. J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.09.002 · Cited by 185
Resistant hypertension—its identification and epidemiology
Sarafidis, P. A., Georgianos, P., & Bakris, G. L. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.260 · Cited by 185
Losartan Increases Bradykinin Levels in Hypertensive Humans
Campbell, D. J., Krum, H., & Esler, M. D. (2005) · Circulation · doi:10.1161/01.cir.0000153269.07762.3b · Cited by 184
(2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328344a7de · Cited by 184
Zelmanovitz, T., Gerchman, F., Balthazar, A. P., Thomazelli, F. C. S., de Matos, J. D., & Canani, L. H. S. (2009) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-1-10 · Cited by 184
Bangalore, S., Fakheri, R., Toklu, B., & Messerli, F. H. (2016) · BMJ · doi:10.1136/bmj.i438 · Cited by 183
Cerebral White Matter Hyperintensities on MRI: Current Concepts and Therapeutic Implications
Ovbiagele, B., & Saver, J. L. (2006) · Cerebrovascular Diseases · doi:10.1159/000093235 · Cited by 183
Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less?
Fischer, M. A., & Avorn, J. (2004) · JAMA · doi:10.1001/jama.291.15.1850 · Cited by 183
Matsui, Y., Eguchi, K., O'Rourke, M. F., Ishikawa, J., Miyashita, H., Shimada, K., & Kario, K. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.131466 · Cited by 182
Gender Differences in Epidemiology, Pathophysiology, and Treatment of Hypertension
Giosia, P. D., Giorgini, P., Stamerra, C. A., Petrarca, M., Ferri, C., & Sahebkar, A. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0716-z · Cited by 182
C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?
Rattazzi, M., Puato, M., Faggin, E., Bertipaglia, B., Zambon, A., & Pauletto, P. (2003) · Journal of Hypertension · doi:10.1097/00004872-200310000-00002 · Cited by 181
IV Diretrizes Brasileiras de Hipertensão Arterial
Júnior, D. M., Gomes, M. A. M., Nobre, F. D., Amodeo, C., Kohlmann, O., Praxedes, J. N., Machado, C. A., Machado, C. A., Pascoal, I., & Magalhães, L. C. (2004) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2004001000004 · Cited by 185
McCullough, P. A., & Soman, S. S. (2005) · Critical Care Clinics · doi:10.1016/j.ccc.2004.12.003 · Cited by 180
Bradley, H. A., Wiysonge, C. S., Volmink, J. A., Mayosi, B. M., & Opie, L. H. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249685.58370.28 · Cited by 179
Chu, K. Y., Lau, T., Carlsson, P.-O., & Leung, P. S. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1022 · Cited by 179
The angiotensin II type 2 receptor in cardiovascular disease
Lemarié, C. A., & Schiffrin, E. L. (2010) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320309347785 · Cited by 179
Campbell, R. T., Jhund, P. S., Castagno, D., Hawkins, N. M., Petrie, M. C., & McMurray, J. J. V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.064 · Cited by 179
Mineralocorticoid receptors in vascular function and disease
McCurley, A., & Jaffe, I. Z. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.014 · Cited by 178
Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
Prasad, A., & Quyyumi, A. A. (2004) · Circulation · doi:10.1161/01.cir.0000141736.76561.78 · Cited by 178
Risk Factor Management in Atrial Fibrillation
Brandes, A., Smit, M. D., Nguyen, B. O., Rienstra, M., & Gelder, I. C. V. (2018) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2018.18.2 · Cited by 180
Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies
Zuo, T., Liu, X., Jiang, L., Mao, S., Yin, X., & Guo, L. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0379-z · Cited by 178
Mahfoud, F., Böhm, M., Azizi, M., Pathak, A., Durand Zaleski, I., Ewen, S., Tsioufis, K., Andersson, B., Blankestijn, P. J., Burnier, M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv192 · Cited by 177
Self-citationSilverman, D. N., Plante, T. B., Infeld, M., Callas, P. W., Juraschek, S. P., Dougherty, G. B., & Meyer, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16598 · Cited by 177
Opelz, G., Zeier, M., Laux, G., Morath, C., & Döhler, B. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050543 · Cited by 177
Lévy, B. I. (2004) · Circulation · doi:10.1161/01.cir.0000096609.73772.c5 · Cited by 176
Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression
Artham, S. M., Lavie, C. J., Milani, R. V., Patel, D. A., Verma, A., & Ventura, H. O. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.05.002 · Cited by 176
Makani, H., Messerli, F. H., Romero, J., Wever-Pinzon, O., Korniyenko, A., Berrios, R. S., & Bangalore, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.034 · Cited by 175
Reboussin, D. M., Allen, N. B., Griswold, M. E., Guallar, E., Hong, Y., Lackland, D. T., Miller, E. (. R., Polonsky, T., Thompson-Paul, A. M., & Vupputuri, S. (2018) · Hypertension · doi:10.1161/hyp.0000000000000067 · Cited by 175
Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes
Grisanti, L. A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01669 · Cited by 175
Abraham, H. M. A., White, C. M., & White, W. B. (2015) · Drug Safety · doi:10.1007/s40264-014-0239-7 · Cited by 175
Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
O’Keefe, J. H., Carter, M. D., & Lavie, C. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.8.741 · Cited by 173
Kim-Mitsuyama, S., Yamamoto, E., Tanaka, T., Zhan, Y., Izumi, Y., Izumiya, Y., Ioroi, T., Wanibuchi, H., & Iwao, H. (2005) · Stroke · doi:10.1161/01.str.0000163084.16505.e3 · Cited by 173
Antihypertensive Therapy and Incidence of Type 2 Diabetes
Padwal, R., & Laupacis, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.247 · Cited by 173
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G. L., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C. S., et al. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.06.001 · Cited by 179
Self-citationMetabolic syndrome: a sympathetic disease?
Schlaich, M., Straznicky, N., Lambert, E., & Lambert, G. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70033-6 · Cited by 171
Furuhashi, M., Ura, N., Takizawa, H., Yoshida, D., Moniwa, N., Murakami, H., Higashiura, K., & Shimamoto, K. (2004) · Journal of Hypertension · doi:10.1097/00004872-200410000-00021 · Cited by 171
Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans
Ojji, D. B., Mayosi, B., Francis, V., Badri, M., Cornelius, V., Smythe, W., Kramer, N., Barasa, F., Damasceno, A., Dzudie, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901113 · Cited by 170
III Diretriz Brasileira de Insuficiência Cardíaca Crônica
Bocchi, E. A., Marcondes‐Braga, F. G., Ayub‐Ferreira, S. M., Rohde, L. E. P., Junior, W. A. D. O., Almeida, D. R., Moreira, M. D. C. V., Bestetti, R. B., Bordignon, S., Azevedo, C., et al. (2009) · Americanae (AECID Library) · doi:10.1590/s0066-782x2009002000001 · Cited by 170
Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35
DePaula, A. L., Macedo, A. L. V., Rassi, N., Machado, C. A., Schraibman, V., Silva, L. Q., & Halpern, A. (2007) · Surgical Endoscopy · doi:10.1007/s00464-007-9472-9 · Cited by 170
Cice, G., Di Benedetto, A., D'Isa, S., D'Andrea, A., Marcelli, D., Gatti, E., & Calabrò, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.105 · Cited by 170
Mohan, M., Al-Talabany, S., McKinnie, A., Mordi, I. R., Singh, J. S. S., Gandy, S. J., Baig, F., Hussain, M. S., Bhalraam, U., Khan, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz203 · Cited by 170
Luther, J. M., Gainer, J. V., Murphey, L. J., Yu, C., Vaughan, D. E., Morrow, J. D., & Brown, N. J. (2006) · Hypertension · doi:10.1161/01.hyp.0000248135.97380.76 · Cited by 169
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.